Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease
Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, su



















